W
W

Wacker


Wiadomości

Rotork, Societe Generale SA, Talanx AG

EUROPE RESEARCH ROUNDUP-Rotork, Societe Generale SA, Talanx AG Aug 23 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Rotork, Societe Generale SA, and Talanx AG, on Wednesday. HIGHLIGHTS * Elkem ASA ELK.OL : Morgan Stanley cuts to equal weight from overweight * Gurit Holding AG GURN.S : Credit Suisse raises to outperform from underperform * Rotork Plc ROR.L : Peel Hunt raises to buy from add * Societe Generale SA SOGN.PA : Morgan S
A
B
B
B
C
C
I
K
P
R
S
S
S
T
U
W
W
A
S
U

Beiersdorf, LSE, Vanquis Banking Group

EUROPE RESEARCH ROUNDUP-Beiersdorf, LSE, Vanquis Banking Group Aug 4 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Beiersdorf, LSE and Vanquis Banking Group, on Friday. HIGHLIGHTS * Beiersdorf AG BEIG.DE : Credit Suisse raises target price to EUR 140 from EUR 135 * Interroll Holding AG INRN.S : Credit Suisse raises target to CHF 2,850p from CHF 2,660p * LSE LSEG.L : Credit Suisse cuts target price to 8,500p from 8,600p * Neste Oy
A
A
A
A
A
B
C
E
E
E
H
H
I
I
L
M
N
N
S
U
U
W
A
A
B
B
B
B
E
I
P

German chemical lobby slashes annual targets as high prices dampen demand

UPDATE 2-German chemical lobby slashes annual targets as high prices dampen demand Forecast sales decline doubles to 14% High prices hit Germany's competitiveness No real growth in sight - VCI President Changes headline; adds VCI president quotes in paragraph 4, 13; Adds analyst and portfolio manager paragraphs 12, 14-15; Adds background on destocking By Andrey Sychev and Patricia Weiss July 21 (Reuters) - German chemicals lobby VCI on Friday trimmed its already grim forecast for annual output a
B
B
L
W

German chemical lobby again trims forecast on high production costs

German chemical lobby again trims forecast on high production costs July 21 (Reuters) - German chemicals lobby VCI trimmed its already grim forecast for the year on Friday, as high energy prices and structural problems for Germany as a business location hamper the industry. The lump risk of "high energy prices and corporate taxes, worsening infrastructure, shortage of skilled workers, lacklustre digitalisation, and bureaucracy madness robs our entrepreneurs of confidence," said VCI president Mar
B
L
W

European chemical lobby warns of "perfect storm" for industry

European chemical lobby warns of "perfect storm" for industry July 19 (Reuters) - European chemical industry council Cefic warned on Tuesday that the industry is facing a "perfect storm" as production volumes are expected to drop by about 8% this year, with no immediate recovery in demand expected soon. "The combination of high energy prices, lack of global demand, and the US Inflation Reduction Act (IRA) means there is simply no business case for investing in Europe now," Cefic Director General
B
C
L
V
W
G

European shares gain as homebuilders surge; UK stocks shine

UPDATE 2-European shares gain as homebuilders surge; UK stocks shine For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window STOXX 600 up 0.3%, rising for second day Real estate groups lead sectoral advance UK's FTSE 100 shines as domestic inflation slows Updated at 1553 GMT By Amruta Khandekar and Shristi Achar A July 19 (Reuters) - European shares closed higher on Wednesday, with UK stocks in the lead after a faster-than-expected slowdown in B
G
K
W
A
E
F
U
G

Wacker Chemie shares fall after it lowered 2023 annual guidance

BUZZ-Wacker Chemie shares fall after it lowered 2023 annual guidance ** Shares in Wacker Chemie WCHG.DE fall 4.5% in early Frankfurt trade after the German chemicals maker on Tuesday cut its outlook for 2023 ** The German company now expects its EBITDA to amount between 800 million euros and 1.0 billion euros ($897.92 million - $1.12 billion) for fiscal year, versus previously expected 1.1 billion to 1.4 billion euros ** "Our expectations have declined primarily due to ongoing weak customer dema
B
C
C
L
V
W

Wacker Chemie Now Expects FY EBITDA To Be Between EUR 800 Mln And EUR 1.0 Bln

BRIEF-Wacker Chemie Now Expects FY EBITDA To Be Between EUR 800 Mln And EUR 1.0 Bln July 18 (Reuters) - WACKER CHEMIE AG WCHG.DE : EXPECTS KEY FINANCIAL PERFORMANCE INDICATORS FOR 2023 TO BE LOWER THAN PREVIOUSLY PROJECTED THIS IS PRIMARILY DUE TO ONGOING WEAK CUSTOMER DEMAND IN A LARGE NUMBER OF INDUSTRIES, CONTINUING INVENTORY-REDUCTION MEASURES
W

Top of the Street: Astrazenca, Georg Fischer, Wacker Chemie

BUZZ-Top of the Street: Astrazenca, Georg Fischer, Wacker Chemie A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank downgrades London-based drugmaker AstraZeneca AZN.L to "hold" from "buy" after the "underwhelming" results of its lung-cancer drug trial published on Monday ** Baader Helvea Equity Research downgrades Georg Fischer GF.S to "add" from "buy" on declining industrial PMI in China, where the Swiss industrial group makes around 25% of
A
H
P
W

HSBC sees 'solar supremacy' in energy sector

BUZZ-HSBC sees 'solar supremacy' in energy sector ** HSBC says solar energy sector's stellar rise is set to continue, seeing the value chain fully supplied for 500GW of annual installations by 2026 ** The IEA predicts investments in solar will for the first time surpass spending on oil production in 2023, the broker says ** "Solar supremacy is building," HSBC says, expecting solar to meet and even exceed many government rollout targets, unlike other low carbon technologies ** It says efforts to
H
W

Stifel sees tough 2023-2024 for chemicals, more profit warnings to come

BUZZ-Stifel sees tough 2023-2024 for chemicals, more profit warnings to come ** Stifel expects tough H2 2023 and FY 2024 for European chemical companies, punctuated by profit warnings as sentiment towards the sector turns back to negative ** It prefers companies with predictable growth, given a cyclical recovery is postponed, with diversified and u
B
B
C
G
K
S
S
W
A

Wacker Biotech And Caeregen Therapeutics To Cooperate On Retina-Related Vision Loss

BRIEF-Wacker Biotech And Caeregen Therapeutics To Cooperate On Retina-Related Vision Loss June 28 (Reuters) - Wacker Chemie AG WCHG.DE : CAEREGEN THERAPEUTICS AND WACKER BIOTECH WILL COLLABORATE ON THE DEVELOPMENT AND MANUFACTURE OF CTR-107 (NOREGEN™), A NOVEL REGENERATIVE THERAPEUTIC FOR THE TREATMENT OF RETINA-RELATED VISION LOSS Further compan
W

Lanxess shares plunge to three-year low after company cuts outlook

UPDATE 1-Lanxess shares plunge to three-year low after company cuts outlook Rewrites throughout with Lanxess, peers' share price moves and comments from industry body June 20 (Reuters) - German speciality chemicals maker Lanxess LXSG.DE slashed its second-quarter and annual core profit forecast, saying it saw no demand recovery in June as customers continued to destock, sending its shares plunging 16% to a three-year low on Tuesday.
B
B
L
W

Wacker Chemie To Expand Semiconductor-Grade Polysilicon Production Capacity In Burghausen

BRIEF-Wacker Chemie To Expand Semiconductor-Grade Polysilicon Production Capacity In Burghausen June 12 (Reuters) - WACKER CHEMIE AG WCHG.DE : TO EXPAND SEMICONDUCTOR-GRADE POLYSILICON PRODUCTION CAPACITY IN BURGHAUSEN PROJECT TO INCREASE EXISTING CLEANING CAPACITY BY WELL OVER 50 PERCENT FROM EARLY 2025 INVESTMENT IN PLANT AND INFRASTRUCTURE EXCEE
W

EU approves $8.7 bln of state aid for tech innovation projects

UPDATE 2-EU approves $8.7 bln of state aid for tech innovation projects Adds details in paragraphs 3-5, EU industry chief in paragraph 7, more companies and countries involved in paragraphs 9-11 By Foo Yun Chee BRUSSELS, June 8 (Reuters) - The European Commission has approved 8.1 billion euros ($8.7 billion) of state aid for microelectronics and communication technology projects as part of the European Union's drive to be at the cutting edge of technological innovation.
A
E
I
N
O
R
W
A
A

Supply chain scrutiny may upend EU solar ambitions

BREAKINGVIEWS-Supply chain scrutiny may upend EU solar ambitions The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Updates to add graphics. By Lisa Jucca MILAN, May 23 (Reuters Breakingviews) - Making the world a greener place through clean energy is hard enough. Doing so while also avoiding human rights violations looks even harder.
R
W

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions May 8 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1945 GMT on Monday: ** Toronto-Dominion Bank's TD.TO handling of "suspicious" customer transactions was behind regulators' refusal to approve the lender's $13.4 billion deal to buy First Horizon FHN.N , the Wall Street Journal reported, citing people familiar with the matter.
B
H
Q
V
W

European shares end higher, lifted by healthcare and bank stocks

UPDATE 2-European shares end higher, lifted by healthcare and bank stocks For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Healthcare, bank stocks lead gains German industrial production falls in March SBB slumps after S&P downgrades to junk Updates to market close By Amruta Khandekar and Sruthi Shankar May 8 (Reuters) - European shares ended higher on Monday, with healthcare and bank stocks in the lead as investors awaited key U.S.
A
E
P
R
W
E
F
U
G

Wacker Chemie acquires Spanish ADL BioPharma

Wacker Chemie acquires Spanish ADL BioPharma May 8 (Reuters) - German chemicals company Wacker Chemie WCHG.DE on Monday said it has acquired 100% of the shares of contract manufacturing company ADL BioPharma. The purchase price for the acquisition exceeds 100 million euros ($110.47 million), Wacker Chemie said in a statement. "This acquisition will strengthen our biotech business and take us one important step closer to meeting the growth targets of our life sciences business," said Wacker Chemi
W

Wacker Purchases Adl Biopharma In Spain, Price Exceeds Eur 100 MLN

BRIEF-Wacker Purchases Adl Biopharma In Spain, Price Exceeds Eur 100 MLN May 8 (Reuters) - WACKER CHEMIE AG WCHG.DE : PURCHASES ADL BIOPHARMA IN SPAIN, STRENGTHENING ITS BIOTECHNOLOGY BUSINESS PURCHASE PRICE EXCEEDS EUR 100 MILLION CEO CHRISTIAN HARTEL: "THIS ACQUISITION WILL STRENGTHEN OUR BIOTECH BUSINESS AND TAKE US ONE IMPORTANT STEP CLOSER TO
W



Warunki

Popularne aktywa

Wyłączenie odpowiedzialności: Każdy z podmiotów należących do XM Group świadczy usługę polegającą wyłącznie na realizacji zleceń i dostępie do naszej internetowej platformy transakcyjnej, umożliwiając danej osobie przeglądanie i/lub korzystanie z treści dostępnych na stronie lub za jej pośrednictwem, co nie ma na celu zmiany lub rozszerzenia tego zakresu, ani nie zmienia i nie rozszerza go. Taki dostęp i korzystanie z niego podlegają w każdej chwili: (i) Warunkom umowy, (ii) Ostrzeżeniom o ryzyku i (iii) Pełnemu wyłączeniu odpowiedzialności. Treści te są zatem podawane wyłącznie jako informacje ogólne. W szczególności należy pamiętać, że treści zawarte na naszej internetowej platformie transakcyjnej nie stanowią oferty ani zaproszenia do zawarcia jakichkolwiek transakcji na rynkach finansowych. Transakcje na każdym rynku finansowym wiążą się ze znacznym poziomem ryzyka dla twojego kapitału.

Wszystkie materiały publikowane na naszej internetowej platformie transakcyjnej są przeznaczone wyłącznie do celów edukacyjnych/informacyjnych i nie zawierają – i nie powinny być uważane za zawierające – porad ani rekomendacji dotyczących finansów, inwestycji, podatków lub transakcji, zapisu naszych cen transakcyjnych, ani też oferty lub zaproszenia do transakcji na jakichkolwiek instrumentach lub niezamówionych promocji finansowych.

Wszelkie treści pochodzące od podmiotów trzecich, jak i treści przygotowane przez XM, takie jak opinie, wiadomości, badania, analizy, ceny i inne informacje lub linki do stron podmiotów trzecich zawarte na tej stronie internetowej są udostępniane na zasadzie „tak, jak jest” jako ogólny komentarz rynkowy i nie stanowią porady inwestycyjnej. W zakresie, w jakim jakakolwiek treść jest interpretowana jako badania inwestycyjne, należy zauważyć i zaakceptować, że treść ta nie była przeznaczona i nie została przygotowana zgodnie z wymogami prawnymi mającymi na celu promowanie niezależności badań inwestycyjnych i jako taka byłaby uważana za komunikat marketingowy w świetle odpowiednich przepisów prawnych i regulacji. Upewnij się, że przeczytałeś(-aś) i rozumiesz nasze dokumenty Powiadomienie o zależnych badaniach inwestycyjnych oraz Ostrzeżenie o ryzyku, dotyczące powyższych informacji, do których można uzyskać dostęp tutaj.

Korzystamy z plików cookie, aby zapewnić użytkownikom optymalne warunki korzystania z naszej strony internetowej. Dowiedz się więcej lub zmień swoje ustawienia plików cookie.

Ostrzeżenie o ryzyku: Twój kapitał jest zagrożony. Produkty z zastosowaniem dźwigni mogą nie być odpowiednie dla każdego inwestora. Zapoznaj się z Ujawnieniem ryzyka.